Jardiance Met 5mg/500mg Tablet is a combination oral antidiabetic medication containing Empagliflozin 5mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting glycosuria and thereby lowering plasma glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic gluconeogenesis and improving peripheral insulin sensitivity, resulting in enhanced glucose uptake and utilization. The synergistic action of these agents provides effective glycemic control, reducing HbA1c levels and aiding in weight management. Jardiance Met is typically prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient. The combination offers convenience and improved adherence compared to separate administration. Common adverse effects include urinary tract infections, genital mycotic infections, gastrointestinal disturbances such as nausea and diarrhea, and a risk of lactic acidosis, particularly in patients with renal impairment or other contraindications. Renal function should be assessed prior to initiation and periodically during treatment. Jardiance Met is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to its components. Careful patient selection and monitoring are essential to optimize therapeutic outcomes and minimize risks.